BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $110.00. The company’s shares closed yesterday at ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...

The week ahead holds earnings releases for many market-moving companies, including names such as Palantir and Super Micro ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the trading week from November 4th to 8th, experts opinion is between volatile to bearish in Dow Jones, S&P 500, and ...